Table 3:
Nested survival models of medication count and risk of hospitalisation
| Unadjusted | Progressively adjusted for additional factors | |||
|---|---|---|---|---|
|
|
||||
| Adjusted for demographics | Adjusted for demographics and severity of illness | Adjusted for demographics, severity of illness, and KPDI Index | ||
| People ageing with HIV (n=9186) | ||||
| Non-ART medication count | 1·08 (1·07–1·09) | 1·08 (1·07–1·09) | 1·07 (1·06–1·08) | 1·06 (1·05–1·07) |
| Age per 10 years | ·· | 1·13 (1·10–1·16) | 0·96 (0·93–0·99) | 0·96 (0·93–0·99) |
| Sex | ||||
| Female | ·· | 1·13 (0·94–1·34) | 1·07 (0·89–1·27) | 1·07 (0·90–1·28) |
| Male | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| Race | ||||
| White, non-Hispanic | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| Black, non-Hispanic | ·· | 1·27 (1·20–1·34) | 1·16 (1·10–1·23) | 1·17 (1·10–1·24) |
| Hispanic | ·· | 1·16 (1·05–1·28) | 1·11 (1·01–1·22) | 1·11 (1·01–1·23) |
| Other | ·· | 0·72 (0·61–0·85) | 0·73 (0·62–0·86) | 0·74 (0·63–0·87) |
| VACS Index 2.0 per 5 points | ·· | ·· | 1·11 (1·10–1·12) | 1·11 (1·10–1·12) |
| KPDI Index score | ||||
| No KPDI | ·· | ·· | ·· | 1·10 (0·97–1·25) |
| KPDI Index quintile 1 | ·· | ·· | ·· | 1·03 (0·94–1·13) |
| KPDI Index quintile 2 | ·· | ·· | ·· | 1 (ref) |
| KPDI Index quintile 3 | ·· | ·· | ·· | 1·12 (1·04–1·21) |
| KPDI Index quintile 4 | ·· | ·· | ·· | 1·14 (1·04–1·26) |
| KPDI Index quintile 5 | ·· | ·· | ·· | 1·12 (0·98–1·28) |
| People ageing without HIV (n=37930) | ||||
| Non-ART medication count | 1·08 (1·07–1·08) | 1·07 (1·07–1·08) | 1·07 (1·06–1·07) | 1·04 (1·03–1·05) |
| Age per 10 years | ·· | 1·00 (0·99–1·02) | 0·83 (0·81–0·84) | 0·82 (0·81–0·84) |
| Sex | ||||
| Female | ·· | 0·91 (0·83–0·99) | 0·83 (0·76–0·91) | 0·85 (0·77–0·92) |
| Male | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| Race | ||||
| White, non-Hispanic | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| Black, non-Hispanic | ·· | 1·29 (1·25–1·33) | 1·24 (1·20–1·28) | 1·26 (1·22–1·29) |
| Hispanic | ·· | 1·07 (1·02–1·13) | 1·11 (1·05–1·16) | 1·12 (1·06–1·17) |
| Other | ·· | 0·57 (0·52–0·63) | 0·59 (0·54–0·65) | 0·60 (0·54–0·66) |
| VACS Index 2.0 per 5 points | ·· | ·· | 1·15 (1·15–1·16) | 1·15 (1·14–1·16) |
| KPDI Index score | ||||
| No KPDI | ·· | ·· | ·· | 0·88 (0·84–0·93) |
| KPDI Index quintile 1 | ·· | ·· | ·· | 0·96 (0·91–1·01) |
| KPDI Index quintile 2 | ·· | ·· | ·· | 1 (ref) |
| KPDI Index quintile 3 | ·· | ·· | ·· | 1·10 (1·05–1·15) |
| KPDI Index quintile 4 | ·· | ·· | ·· | 1·22 (1·15–1·28) |
| KPDI Index quintile 5 | ·· | ·· | ·· | 1·34 (1·25–1·43) |
Data are hazard ratios with 95% CIs in parentheses. ART=antiretroviral therapy. KPDI=known pairwise drug interaction. VACS= Veterans Aging Cohort Study.